Global Restless Legs Syndrome Market 2015-2019 Featuring Boehringer Ingelheim, GlaxoSmithKline, UCB & XenoPort

News provided by

Research and Markets

30 Jun, 2015, 17:21 GMT

DUBLIN, June 24, 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/646k6k/global_restless) has announced the addition of the "Global Restless Legs Syndrome Market 2015-2019" report to their offering.

The analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.

This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.

The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors.

According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. This creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market.

Further, the report states that the unknown disease etiology is one of the major challenges for vendors in the market.

Key vendors

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • XenoPort

Other prominent vendors

  • Alexza Pharmaceuticals
  • Astellas Pharma
  • Axxonis Pharma
  • Bayer Healthcare
  • Impax Pharmaceuticals
  • Luitpold Pharmaceuticals
  • Merz Pharmaceuticals
  • Mundipharma
  • Newron Pharmaceuticals
  • Serina Therapeutics
  • Teva Neuroscience

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Product Profiles
  6. Introduction
  7. Disease Overview
  8. Pipeline Analysis
  9. Commercial Opportunities
  10. Key Brand Analysis
  11. Market Landscape
  12. Market Segmentation by Class of Drugs
  13. Geographical Segmentation
  14. Buying Criteria
  15. Market Growth Drivers
  16. Drivers and their Impact
  17. Market Challenges
  18. Impact of Drivers and Challenges
  19. Market Trends
  20. Trends and their Impact
  21. Vendor Landscape
  22. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/646k6k/global_restless

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com